VASOTEC IV SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

ENALAPRILAT

Saadav alates:

SANDOZ CANADA INCORPORATED

ATC kood:

C09AA02

INN (Rahvusvaheline Nimetus):

ENALAPRIL

Annus:

1.25MG

Ravimvorm:

SOLUTION

Koostis:

ENALAPRILAT 1.25MG

Manustamisviis:

INTRAVENOUS

Ühikuid pakis:

2ML

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0118001001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2008-04-03

Toote omadused

_ _
VASOTEC
®
IV
Page 1 of 30
PRODUCT MONOGRAPH
Pr
VASOTEC
® IV
ENALAPRILAT INJECTION
1.25 MG/ML IN 2 ML VIALS
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Sandoz Canada Inc.
Date of Revision: September 20, 2013
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
SUBMISSION CONTROL NO: 167061
_ _
VASOTEC
®
IV
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................................................
3
SUMMARY
PRODUCT
INFORMATION
..............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS
.........................................................................................................................................
7
DRUG
INTERACTIONS
........................................................................................................................................
13
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
14
OVERDOSAGE
......................................................................................................................................................
15
ACTION
AND
CLINICAL
PHARMACOLOGY
...................................................................................................
15
STORAGE
AND
STABILITY
................................................................................................................................
17
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING
...........................